Literature DB >> 11513328

Mechanism-based inactivators as probes of cytochrome P450 structure and function.

U M Kent1, M I Juschyshyn, P F Hollenberg.   

Abstract

The cytochromes P450 superfamily of enzymes is a group of hemeproteins that catalyze the metabolism of an extensive series of compounds including drugs, chemical carcinogens, fatty acids, and steroids. They oxidize substrates ranging in size from ethylene to cyclosporin. Although significant efforts have been made to obtain structural information on the active sites of the microbial P450s, relatively little is currently known regarding the identities of the critical amino acid residues in the P450 active sites that are involved in substrate binding and catalysis. Since information on the crystal structures of the eukaryotic P450s has been relatively limited, investigators have used a variety of other techniques in attempts to elucide the structural features that play a role in the catalytic properties and substrate specificity at the enzyme active site. These include site-directed mutagenesis, natural mutations, homology modeling, mapping with aryl-iron complexes, affinity and photoaffinity labeling, and mechanism-based inactivators. A variety of different mechanism-based inactivators have proven to be useful in identifiying active site amino acid residues involved in substrate binding and catalysis. In this review we present a sampling of the types of studies that can be conducted using mechanism-based inactivators and highlight studies with several classes of compounds including acetylenes, isothiocyanates, xanthates, aminobenzotriazoles, phencyclidine, and furanocoumarins. Labeled peptides isolated from the inactivated proteins have been analyzed by N-terminal amino acid sequencing in conjunction with mass spectrometry to determine the sites of covalent modification. Mechanistic studies aimed at identifying the basis for the inactivation following adduct formation are also presented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513328     DOI: 10.2174/1389200013338478

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  18 in total

1.  Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity.

Authors:  Sean C Gay; Haoming Zhang; P Ross Wilderman; Arthur G Roberts; Tong Liu; Sheng Li; Hsia-Lien Lin; Qinghai Zhang; Virgil L Woods; C David Stout; Paul F Hollenberg; James R Halpert
Journal:  Biochemistry       Date:  2011-05-13       Impact factor: 3.162

Review 2.  Anticancer activity of natural and synthetic acetylenic lipids.

Authors:  Valery M Dembitsky
Journal:  Lipids       Date:  2006-10       Impact factor: 1.880

3.  Roles of Residues F206 and V367 in Human CYP2B6: Effects of Mutations on Androgen Hydroxylation, Mechanism-Based Inactivation, and Reversible Inhibition.

Authors:  Hsia-Lien Lin; Haoming Zhang; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2016-08-18       Impact factor: 3.922

4.  The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme.

Authors:  Takahiro Murai; Christopher A Reilly; Robert M Ward; Garold S Yost
Journal:  Chem Res Toxicol       Date:  2010-08-16       Impact factor: 3.739

5.  Identification of Mechanism-Based Inactivation in P450-Catalyzed Cyclopropanation Facilitates Engineering of Improved Enzymes.

Authors:  Hans Renata; Russell D Lewis; Michael J Sweredoski; Annie Moradian; Sonja Hess; Z Jane Wang; Frances H Arnold
Journal:  J Am Chem Soc       Date:  2016-09-14       Impact factor: 15.419

6.  Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2.

Authors:  Pierre Lafite; Sylvie Dijols; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Arch Biochem Biophys       Date:  2007-04-10       Impact factor: 4.013

7.  The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation.

Authors:  Yasushi Yoshigae; Chitra Sridar; Ute M Kent; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2013-01-31       Impact factor: 3.922

8.  Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.

Authors:  Ute M Kent; Hsia-Lien Lin; Danielle E Mills; Kelly A Regal; Paul F Hollenberg
Journal:  Chem Res Toxicol       Date:  2006-02       Impact factor: 3.739

9.  Chemical proteomic probes for profiling cytochrome p450 activities and drug interactions in vivo.

Authors:  Aaron T Wright; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2007-09

10.  Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants.

Authors:  Thomas M Polasek; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.